These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11594457)

  • 1. Regulation of tumor growth by IFN-gamma in cancer immunotherapy.
    Beatty GL; Paterson Y
    Immunol Res; 2001; 24(2):201-10. PubMed ID: 11594457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytes.
    Boselli D; Ragimbeau J; Orlando L; Cappello P; Capello M; Ambrogio C; Chiarle R; Marsili G; Battistini A; Giovarelli M; Pellegrini S; Novelli F
    Immunol Lett; 2010 Nov; 134(1):17-25. PubMed ID: 20709103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.
    Alspach E; Lussier DM; Schreiber RD
    Cold Spring Harb Perspect Biol; 2019 Mar; 11(3):. PubMed ID: 29661791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
    Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
    Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
    J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma.
    Nagao M; Nakajima Y; Kanehiro H; Hisanaga M; Aomatsu Y; Ko S; Tatekawa Y; Ikeda N; Kanokogi H; Urizono Y; Kobayashi T; Shibaji T; Kanamura T; Ogawa S; Nakano H
    Hepatology; 2000 Sep; 32(3):491-500. PubMed ID: 10960440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
    Xiao H; Peng Y; Hong Y; Huang L; Guo ZS; Bartlett DL; Fu N; Munn DH; Mellor A; He Y
    J Immunol; 2013 Jun; 190(11):5866-73. PubMed ID: 23610140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype.
    Wang L; Wei Y; Jin Z; Liu F; Li X; Zhang X; Bai X; Jia Q; Zhu B; Chu Q
    Clin Exp Med; 2024 May; 24(1):102. PubMed ID: 38758367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis.
    Lu Y; Yang W; Qin C; Zhang L; Deng J; Liu S; Qin Z
    J Immunol; 2009 Nov; 183(10):6413-21. PubMed ID: 19841170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.
    Castro F; Cardoso AP; Gonçalves RM; Serre K; Oliveira MJ
    Front Immunol; 2018; 9():847. PubMed ID: 29780381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy.
    Han J; Wu M; Liu Z
    Front Immunol; 2023; 14():1190333. PubMed ID: 37275859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disorders of interferon-gamma activation pathways: new group of primary immune deficiency diseases].
    Erdös M; Maródi L
    Orv Hetil; 2001 Nov; 142(46):2557-61. PubMed ID: 11770174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells.
    Koumbadinga GA; Désormeaux A; Adam A; Marceau F
    Eur J Pharmacol; 2010 Nov; 647(1-3):117-25. PubMed ID: 20813106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Hypoxia Reduces IFN-γ-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model.
    Murthy A; Gerber SA; Koch CJ; Lord EM
    Immunohorizons; 2019 Apr; 3(4):149-160. PubMed ID: 31356176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1 down-regulates IFN-gamma R2 chain surface expression and desensitizes IFN-gamma/STAT-1 signaling in human T lymphocytes.
    Bernabei P; Bosticardo M; Losana G; Regis G; Di Paola F; De Angelis S; Giovarelli M; Novelli F
    Blood; 2003 Oct; 102(8):2933-9. PubMed ID: 12842994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a New Cholesterol-Binding Site within the IFN-γ Receptor that is Required for Signal Transduction.
    Morana O; Nieto-Garai JA; Björkholm P; Bernardino de la Serna J; Terrones O; Arboleya A; Ciceri D; Rojo-Bartolomé I; Blouin CM; Lamaze C; Lorizate M; Contreras FX
    Adv Sci (Weinh); 2022 Apr; 9(11):e2105170. PubMed ID: 35166455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of IFN-γ and granzyme-B production by in "sitro" technology.
    Galassi C; Manic G; Musella M; Sistigu A; Vitale I
    Methods Enzymol; 2020; 631():391-414. PubMed ID: 31948559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.